https://www.nejm.org/doi/pdf/10.1056...icleTools=true
Direktno sa The new england journal of medicine"CONCLUSIONS
The mRNA-1273 vaccine induced anti–SARS-CoV-2 immune responses in all participants, and no trial-limiting safety concerns were identified. These findings support further development of this vaccine. (Funded by the National Institute of Allergy and Infectious Diseases and others; mRNA-1273 ClinicalTrials.gov number, NCT04283461)."
Bookmarks